Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Abroad (travel likely)RecruitingPHASE2

Conditions

TNBC - Triple-Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Anhui Medical University, Hefei, China
Contact: Study coordinator (Yin Chen)
Zhongshan Hospital, Fudan University, Shanghai, China
Contact: Study coordinator (Wei Zhu)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Aarau, Switzerland · Basel, Switzerland

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast Cancer · Triple Negative Breast Cancer · Camrelizumab

Abroad (travel likely)RecruitingPHASE2

Zhengzhou, China

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Triple-negative Breast Cancer · Bone Metastases

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China